Clinical Trials Logo

Clinical Trial Summary

Empyema is associated with a wide range of complication and mortality. It is defined by either a positive pleural fluid culture or grossly pus appearance. However, little is known about the differences in aetiology and outcome between culture-positive empyema (CPE) and culture-negative empyema (CNE). The aim of the current study is to look at the local prevalence of CNE, and compare the clinical outcome between CPE and CNE.


Clinical Trial Description

Pneumonia is a common disease and it ranked second as the leading cause of death in Hong Kong in 2016. Among patients suffering from acute pneumonia, up to 57% of them would develop parapneumonic effusion. Without proper treatment, parapneumonic effusion would progress into empyema, which is a clinical emergency. Empyema leads to a longer length of hospital stay, a higher rate of complication and mortality than uncomplicated parapneumonic effusion.

The mainstay of treatment for empyema is antibiotics and drainage. Therefore, identification of causative microorganism is important in guiding the choice of antibiotics. The common bacterial culprits, for community acquired and hospital acquired, were identified by various local and international studies. However, the aetiological agents were still unknown in up to 40% of cases. In addition, the clinical outcomes between culture negative empyema (CNE) and culture positive empyema (CPE) are largely unknown. Data from one Taiwanese study suggested that patients with CPE had a higher in-hospital mortality than those with CNE. However, the primary objective of this study was not putting on the importance of CNE. Therefore, data on outcome of CNE patients remain largely uncertain, either worldwide and local population.

The aim of the current study is to look at the local prevalence of CNE, and compare the clinical outcome between CPE and CNE. Through more understanding of CNE, the clinical management of this patient group may be altered and a better patient outcome is anticipated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04477980
Study type Observational
Source Chinese University of Hong Kong
Contact
Status Completed
Phase
Start date May 3, 2018
Completion date May 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05546762 - Trial of Antiseptic Irrigation for Pleural Infection Phase 2
Completed NCT06325904 - Uniportal VATS Versus Chest Tube for Early Empyema N/A
Completed NCT05204537 - The Role of Surgery in Patients With Coronavirus Disease - 19 (COVID-19) Related Thoracic Complications
Completed NCT03583931 - Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication N/A
Completed NCT02958683 - Chest Wall Motion Analysis in Disease
Recruiting NCT02165891 - Comparison of Intrapleural Urokinase and Video-Assisted Thorascopic Surgery in the Treatment of Parapneumonic Pleural Effusion in Children Phase 3
Completed NCT01246453 - Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema Phase 4
Recruiting NCT03584113 - VATS Decortication Versus IR Guided Chest Tube Insertion With Fibrinolytics for the Management of Empyema N/A
Completed NCT03873766 - Management of Pleural Space Infections Phase 4